Brain Imaging Profiling for Neurotransmitter-Targeted Depression Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mental health treatments for depressive disorders are often ineffective and can exacerbate the condition due to a lack of precise methods to identify and address the underlying molecular causes, particularly neurotransmitter deficiencies, leading to inefficient therapies that fail to match behavioral and pharmacological interventions to the individual's specific brain reward system impairments.
Innovation Solution
A system and method utilizing brain imaging techniques and subjective emotion data to translate emotional states into brain reward system molecules, such as neurotransmitters, to identify deficiencies and create personalized treatment plans tailored to the identified molecular causes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional mental health treatments are applied without identifying specific molecular causes, then treatment coverage is broad and accessible, but treatment efficacy is low and may worsen the condition
Solution Approach 1:
The patent segments the undifferentiated approach to depression treatment into distinct molecular subtypes based on neurotransmitter deficiencies (serotonin, dopamine, norepinephrine, etc.). By dividing depression into specific molecular categories, the system enables targeted interventions for each subtype rather than applying uniform treatments to all patients, thereby improving treatment efficacy while maintaining manageable diagnostic complexity through systematic classification.
Solution Approach 2:
The patent changes the diagnostic parameter from general symptom assessment to specific molecular marker identification through brain imaging. By measuring neurotransmitter levels and receptor densities as quantitative parameters, the system transforms the diagnostic process into a precise scientific measurement approach, enabling reliable treatment selection based on objective molecular profiles rather than subjective clinical judgment alone.
2Measurement precision
If brain imaging techniques are used to identify neurotransmitter deficiencies, then treatment precision is improved, but diagnostic time and resource requirements increase
Solution Approach 1:
The patent performs preliminary brain imaging and molecular profiling during the initial diagnostic phase to establish the patient's neurotransmitter baseline before treatment begins. By completing these precise measurements upfront rather than during treatment adjustment, the system eliminates repeated imaging sessions and accelerates the path to targeted treatment, reducing overall diagnostic time while maintaining high measurement precision.
3Productivity
If personalized treatment plans based on molecular profiling are implemented, then treatment effectiveness increases, but system complexity and implementation difficulty increase
Solution Approach 1:
The patent develops a universal molecular profiling platform that can identify multiple neurotransmitter systems (serotonin, dopamine, norepinephrine, GABA, glutamate) and receptor types within a single integrated diagnostic workflow. This multi-functional system handles diverse molecular markers through standardized imaging and analysis procedures, enabling personalized treatment across different depression subtypes without requiring separate diagnostic systems for each neurotransmitter, thus managing system complexity while maintaining high treatment effectiveness.
Data Source
AI summary
Disclosed herein are systems and methods for evaluating the underlying molecular (e.g., brain reward system molecules) cause for a depressive disorder and developing a treatment plan based on the identified molecular cause. In one or more examples, the systems and methods described herein can utilize any combination of brain imaging techniques, subjective emotion data taken from a patient, and/or one or more algorithms for translating emotional states to brain reward system molecules (e.g., neurotransmitters) to determine an underlying molecular cause for a depressive disorder of a patient. Once the underlying molecular cause of the depressive disorder of the patient is determined, a treatment plan that includes both behavioral and pharmacological aspects can be selected based on the identity of the reward system molecule that is determined to be deficient and the level of deficiency.